Farmingdale, NY, May 20, 2014 --(PR.com
)-- Dr. Belinda Tsao-Nivaggioli is the Chief Executive Officer of Avicenca Group, Inc. Avicenca is a biotechnology company that develops products based on their understanding of the regulation of cellular energy processes. The company has broad applications in both pharmaceuticals and dermaceuticals. Their pharmaceutical program is centered on rare neurological disorders (orphan diseases) in particular, ALS (Amyotrophic Lateral Sclerosis) also known as Lou Gehrig’s disease. Prior to her role as Chief Executive Officer, Dr. Tsao-Nivaggioli served as COO during which time she was credited with launching the company’s OTC program. Before joining Avicenca Group, she was manager of research and development for Gillette’s Oral–B division where she developed and commercialized several oral care products. Dr. Tsao-Nivaggioli earned her A.B. with Honors at Oberlin College, her M.S. and Ph.D. in Bio-Organic Chemistry at the University of Toronto. Her Post-doctoral research was completed at the Massachusetts Institute of Technology. Dr. Tsao-Nivaggioli is affiliated with the American Chemical Society.
The Professional of the Year membership in America’s Registry is awarded to those candidates who have achieved recognition in their respective industry or profession for their accomplishments and who have established a commendable reputation. This membership honors individuals who have reached the highest standards of business practices and, as such, should be recognized for their standings in the business world. America’s Registry is pleased to honor them.